Phase 1 clinical trial evaluating efficacy and safety of XNW5004 in patients with lymphoma
Latest Information Update: 10 Apr 2023
At a glance
- Drugs XNW 5004 (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Apr 2023 New trial record
- 06 Apr 2023 According to an Evopoint Biosciences media release, Interim results of this Phase 1 study were presented at the ASH meeting in December, 2022.